Among product type segment, metered dose inhalers segment in the global respiratory inhaler market is estimated to account for a majority revenue US$ 11,672.7 Mn in 2017. The manual technology segment is estimated to account for revenue contribution of US$ 26,180.2 Mn in 2017.
Respiratory inhaler is small, handheld devices used for consuming medicines through inhaling. The advantage of inhaler is it can be used to consume small amount dose which reduces the side effect of the medicine. It is used in treatment of asthma, chronic obstructive pulmonary disease, pulmonary arterial hypertension, and cystic fibrosis.
Increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease and increasing in air pollution due to rapid urbanization and industrialization are factors driving the growth of global respiratory inhaler market over the forecast period.
However, factors such as fewer trained or experienced medical practitioners and high cost of inhalers are some factors expected to hamper growth of the global respiratory inhalers market over the forecast period.
Some prominent players in the global respiratory inhaler market include AstraZeneca Plc., Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline Plc., Koninklijke Philips N.V., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Omron Healthcare Europe B.V., PARI Medical Holding, and H&T PRESSPART